stockrow
Saturday 7 November 2026
Export ANL’s income statement to Excel — free account
Adlai Nortye Ltd. Sponsored ADR
Adlai Nortye Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.0 million, roughly unchanged from fiscal 2023.
10.34
0.66
+6.82%
Follow ANL
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 46 | — | 5 | — | 5 | — | (42.5%) | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | 100.00 | — | 100.00 | — | 100.00 | — | 0.0 pt | ||||||
| EBT | — | — | — | — | — | (57) | (59) | (109) | (52) | (36) | — | (11.0%) | ||||||
| EBT margin, % | — | — | — | — | — | (123.95) | 0.00 | (2,184.56) | 0.00 | (710.56) | — | (586.6) pt | ||||||
| Net income | — | — | — | — | — | (57) | (59) | (109) | (52) | (36) | (87) | (11.0%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 5.39 | 0.00 | 0.35 | 0.00 | 0.16 | — | (58.7%) | |||||
| Earnings | — | — | — | — | — | (6.68) | (6.93) | (7.26) | (1.62) | (1.11) | — | (36.2%) | ||||||
| Cash flow | — | — | — | — | — | (0.36) | (5.10) | (3.92) | (1.62) | (1.05) | 0.00 | +30.8% | ||||||
| Capex | — | — | — | — | — | (0.13) | (0.15) | (0.01) | 0.00 | (0.01) | 0.00 | (54.2%) | ||||||
| Free cash flow | — | — | — | — | — | (0.49) | (5.24) | (3.94) | (1.63) | (1.05) | 0.00 | +21.1% | ||||||
| Book value | — | — | — | — | — | (21.87) | (28.45) | 5.19 | 0.80 | (0.26) | 0.00 | (67.0%) | ||||||
| Shares, m | — | — | — | — | — | 8 | 8 | 14 | 32 | 32 | — | +39.3% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | 0.00 | — | 0.00 | — | 0.00 | 0.00 | 0.0 | ||||||
| EV/Sales | — | — | — | — | — | 0.00 | — | 0.00 | — | 0.00 | 0.00 | 0.0 | ||||||
| EV/FCF | — | — | — | — | — | 0.00 | — | 0.00 | — | (0.01) | 1.78 | 0.0 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (3) | (43) | (57) | (52) | (33) | (116) | +82.2% | |||||
| Capex | — | — | — | — | — | (1) | (1) | 0 | 0 | 0 | (1) | (36.1%) | ||||||
| Free cash flow | — | — | — | — | — | (4) | (44) | (57) | (52) | (34) | (116) | +68.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 107 | (246) | 52 | 19 | (15) | 216 | n/m | |||||
| Net debt | — | — | — | — | — | (105) | (59) | (68) | (34) | 2 | (207) | n/m | ||||||
| Shareholders’ equity | — | — | — | — | — | (185) | (241) | 75 | 25 | (8) | 215 | (54.0%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | 0.00 | (57.56) | (107.73) | (51.49) | (67.22) | 0.00 | (67.2) pt | |||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | (615.01) | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | 0.00 | 26.21 | 123.26 | (103.19) | (414.01) | 0.00 | (414.0) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | 130 | 127 | 123 | 109 | — | (5.7%) | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.04 | 0.00 | 0.05 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025
Adlai Nortye Ltd. Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| IMMX Immix Biopharma, Inc. | $596.9M | — (loss-making) | — | — | n/m | −116.22% (below 0%: shrinking) | — | 0.00% | Compare |
| OBX Obsidian Therapeutics, Inc | $593.0M | — | — | — | n/m | — | — | 0.00% | Compare |
| OLMA Olema Pharmaceuticals, Inc. | $591.5M | — (loss-making) | — | — | n/m | −54.33% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| APMD Apnimed, Inc. | $589.5M | 0.8× | 4.6× | — | — | — | 89.98% | (96.89%) | Compare |
| NVCT Nuvectis Pharma, Inc. | $579.8M | — (loss-making) | — | — | n/m | −34.57% (below 0%: shrinking) | — | 0.00% | Compare |
| ANL Adlai Nortye Ltd. Sponsored ADR | $568.5M | — | — | — | — | +46.03% (above 0%: growing) | — | — | |
| ACRS Aclaris Therapeutics, Inc. | $559.5M | — (loss-making) | — (loss-making) | −55.11% (below 0%: shrinking) | n/m | −119.93% (below 0%: shrinking) | 0.00% | (1,441.19%) | Compare |
| IAM Iambic Therapeutics, Inc. | $551.7M | — | — | — | — | — | — | — | Compare |
| BCAX Bicara Therapeutics Inc. | $542.0M | — (loss-making) | — | — | n/m | −72.95% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $584.6M | — | — | — | — | −72.95% | 0.00% | 0.00% |